HealthLeaders Media October 14, 2019
Revenue opportunities for health systems and hospitals include manufacturing gene therapies on their own or in partnership with biotechnology companies.
After biotechnology companies or healthcare organizations receive approval for gene therapies, there are three key capabilities to bring the therapies to market, a new PwC Health Research Institute report says.
Gene therapies modify patient genes or cells to treat or cure disease. Over the next decade, the number of patients who will have received gene therapies is expected to reach 500,000.
Health systems and hospitals are playing a crucial role in the development of gene therapies, including autologous therapies that take cells from patients that are manipulated then reintroduced to the body, the PwC Health Research Institute report says.
“In...
Today's Sponsors
Today's Sponsor